Skip to main content
Terug
SNY logo

Sanofi

Datakwaliteit: 100%
SNY
NASDAQ Healthcare Drug Manufacturers - General
€ 44,77
▲ € 0,17 (0,38%)
Marktkapitalisatie: 109,03B
Ook genoteerd als SNYNF OTC
Dagbereik
€ 44,50 € 45,25
52-Weeksbereik
€ 43,32 € 56,93
Volume
3.063.026
50D / 200D Gem.
€ 46,55 / € 48,31
Vorige Slotkoers
€ 44,60

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 14,0 0,4
P/B 1,5 2,9
ROE % 10,5 3,8
Net Margin % 16,7 3,9
Rev Growth 5Y % 4,5 10,0
D/E 0,3 0,2

Koersdoel Analisten

Hold
€ 57,02 +27.4%
Low: € 48,07 High: € 64,00
Forward K/W
10,6
Forward WPA
€ 4,23
WPA Groei (sch.)
+0,0%
Omzet Sch.
48 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 6,02
€ 5,74 – € 6,53
58 B 2
FY2029 € 5,47
€ 5,21 – € 5,93
56 B 4
FY2028 € 4,94
€ 4,71 – € 5,36
53 B 3

Belangrijkste Punten

Revenue grew 4,50% annually over 5 years — modest growth
Earnings grew 40,52% over the past year
ROE of 10,50% — decent returns on equity
Net margin of 16,72% shows strong profitability
Debt/Equity of 0,31 — conservative balance sheet
Generating 8,89B in free cash flow

Groei

Revenue Growth (5Y)
4,50%
Revenue (1Y)5,49%
Earnings (1Y)40,52%
FCF Growth (3Y)1,45%

Kwaliteit

Return on Equity
10,50%
ROIC5,11%
Net Margin16,72%
Op. Margin13,58%

Veiligheid

Debt / Equity
0,31
Current Ratio1,09
Interest Coverage11,73

Waardering

P/E Ratio
13,96
P/B Ratio1,53
EV/EBITDA19,41
Dividend Yield0,05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5,49% Revenue Growth (3Y) 5,95%
Earnings Growth (1Y) 40,52% Earnings Growth (3Y) 20,29%
Revenue Growth (5Y) 4,50% Earnings Growth (5Y) 5,85%
Profitability
Revenue (TTM) 46,72B Net Income (TTM) 7,81B
ROE 10,50% ROA 6,16%
Gross Margin 72,34% Operating Margin 13,58%
Net Margin 16,72% Free Cash Flow (TTM) 8,89B
ROIC 5,11% FCF Growth (3Y) 1,45%
Safety
Debt / Equity 0,31 Current Ratio 1,09
Interest Coverage 11,73 Dividend Yield 0,05%
Valuation
P/E Ratio 13,96 P/B Ratio 1,53
P/S Ratio 2,33 PEG Ratio -1,66
EV/EBITDA 19,41 Dividend Yield 0,05%
Market Cap 109,03B Enterprise Value 123,16B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 46,72B 44,29B 41,62B 40,56B 39,18B
Net Income 7,81B 5,56B 5,40B 8,37B 6,22B
EPS (Diluted) 2,03 2,19 2,15 3,18 2,49
Gross Profit 33,79B 31,08B 28,99B 28,68B 26,92B
Operating Income 6,34B 7,25B 6,96B 10,16B 8,13B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 126,81B 132,80B 126,46B 126,72B 120,24B
Total Liabilities 55,10B 54,94B 52,11B 51,57B 51,21B
Shareholders' Equity 71,38B 77,51B 74,04B 74,78B 68,68B
Total Debt 21,79B 17,91B 18,70B 21,21B 22,41B
Cash & Equivalents 7,66B 7,44B 8,71B 12,74B 10,10B
Current Assets 30,95B 42,59B 30,66B 34,03B 30,56B
Current Liabilities 28,35B 29,16B 24,19B 23,96B 21,30B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#501 of 1024
46

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026